Patent · US Active

Method for improving the stability of purified Factor VIII after reconstitution

US10881717B2 · kind B2 · utility

3Cited by

13References

24Claims

0Family size

Assignee

CSL LIMITED · AU

Inventors

Carsten Horn · Ettenheim, DE
Sabine Zollner · Muri, CH
Hubert Metzner · Marburg, DE
Stefan Schulte · Marburg, DE

Key dates

Filing date	Dec 3, 2019
Grant date	Jan 5, 2021
Priority date	—
Expiry date	Dec 3, 2039

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K14/755
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present disclosure relates to a method for increasing the stability of a Factor VIII molecule after purification, lyophilization and reconstitution, comprising preventing proteolytic cleavage of the Factor VIII molecule into a first fragment comprising essentially the A1 domain and the A2 domain and a second fragment comprising essentially the A3 domain, the C1 domain and the C2 domain throughout manufacturing the Factor VIII molecule. The disclosure further pertains to a method for improving the bioavailability of Factor VIII after intravenous and non-intravenous injection.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.